Last reviewed · How we verify
TMX-SMX (Bactrim(R))
TMX-SMX (trimethoprim-sulfamethoxazole) is a fixed-dose combination antibiotic that inhibits bacterial folate synthesis by blocking dihydrofolate reductase and dihydropteroate synthase.
TMX-SMX (trimethoprim-sulfamethoxazole) is a fixed-dose combination antibiotic that inhibits bacterial folate synthesis by blocking dihydrofolate reductase and dihydropteroate synthase. Used for Urinary tract infections, Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment, Bacterial infections (respiratory, gastrointestinal, skin and soft tissue).
At a glance
| Generic name | TMX-SMX (Bactrim(R)) |
|---|---|
| Sponsor | Department of Medical Services Ministry of Public Health of Thailand |
| Drug class | Sulfonamide antibiotic combination |
| Target | Dihydrofolate reductase; dihydropteroate synthase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Trimethoprim inhibits bacterial dihydrofolate reductase, preventing the conversion of dihydrofolate to tetrahydrofolate, which is essential for nucleotide synthesis. Sulfamethoxazole inhibits dihydropteroate synthase, blocking the synthesis of dihydrofolate from para-aminobenzoic acid. Together, these agents provide synergistic bactericidal activity against a broad spectrum of gram-positive and gram-negative bacteria.
Approved indications
- Urinary tract infections
- Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment
- Bacterial infections (respiratory, gastrointestinal, skin and soft tissue)
- Toxoplasmosis prophylaxis in immunocompromised patients
Common side effects
- Rash
- Nausea
- Vomiting
- Diarrhea
- Stevens-Johnson syndrome
- Hepatotoxicity
- Hematologic abnormalities (thrombocytopenia, leukopenia)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: